Structure Therapeutics disclosed that its daily obesity pill led patients to lose about 16% of their body weight relative to placebo after 44 weeks
Source
Stat News
Opens original article in a new tab
A redesigned cancer immunotherapy is showing striking early results after decades of disappointment with similar drugs. Researchers engineered a more powerful CD40 agonist antibody and changed how it’s delivered—injecting it directly into tumors instead of into the bloodstream. In a small clinical trial of 12 patients with metastatic cancers, six saw their tumors shrink and two experienced complete remission.
A new UCLA Health study suggests that long-term exposure to the pesticide chlorpyrifos may dramatically raise the risk of Parkinson’s disease. Researchers found that people living in areas with sustained exposure had more than 2.5 times the likelihood of developing the disorder. Lab experiments reinforced the finding: animals exposed to the chemical developed movement problems, lost dopamine-producing neurons, and showed the same toxic protein buildup seen in Parkinson’s patients.
(MedPage Today) -- When MRI offered no clear answer in suspected prostate cancer, the use of prostate-specific membrane antigen (PSMA)-PET/CT showed promise for reducing the number of biopsies without compromising the diagnosis of significant malignancies...
(MedPage Today) -- For patients with obesity and atrial fibrillation (Afib), GLP-1 receptor agonist drugs may be the weight loss approach that better addresses their arrhythmia, observational data suggested. People who came out of catheter ablation...